mRNA 백신이 코로나바이러스 관리에 사용되었던 그 바쁜 시기부터 2019년에는 임상 연구자들이 암 질환 치료에 mRNA 백신을 사용하려는 의도로 열심히 연구하고 있습니다. 코로나바이러스 치료용 mRNA 백신의 승리를 바탕으로 많은 연구자들은 최첨단 mRNA 백신이 독점적인 작용기전으로 인해 암 환자 치료에 사용될 수 있다고 믿었습니다. 따라서 mRNA 암백신 시장은 향후 수년간 더욱 확대될 것으로 예상됩니다. 현재 이 분야 시장은 미국과 중국에 연구개발 측면에서 존재하지만, 전임상시험과 임상시험에서 알 수 있듯이 유럽 국가와 같은 기타 지역도 신흥 지역입니다.
현재까지 mRNA 암백신은 세계 시장에 출시되지 않았으며, 두 개의 mRNA 백신 후보인 CMB-305와 mRNA 4157의 접합체가 개발 후기 단계(3상)에 있으므로 향후 5-7년 내에 획기적인 mRNA 암백신이 출시될 것으로 예상됩니다. 이 세계 시장에 진입할 것으로 예상되며, 첫 번째 mRNA 암백신이 승인되면 12-18개월내 1억 달러의 매출을 달성할 수 있을 것으로 예상됩니다.
지금까지 mRNA 암백신 분야는 이 혁신적인 치료법의 변혁적 잠재력과 함께 연구개발의 괄목할 만한 진전에 힘입어 전진적인 성장을 이루었습니다. 축적된 연구에 따르면 mRNA 암백신은 암을 치료할 수 있는 잠재력을 가지고 있으며, 더 안전하고 내약성이 좋은 프로파일을 보여 새로운 길을 열어주고 있습니다. 혈액암 치료도 머지않아 mRNA 백신을 이용한 치료가 가능해질 것입니다.
세계 시장에서 mRNA 암백신 개발은 순조롭게 진행되고 있지만, 장기적인 효과와 다른 치료법과의 경쟁 등 많은 어려움과 아킬레스건을 안고 있습니다. 반면, 임상시험 파이프라인이 풍부하기 때문에 mRNA 암백신 분야는 앞으로 열광적인 활기를 띌 것으로 예상되며, 이는 제약사들에게 mRNA 암백신 분야를 발전시킬 수 있는 기회로 작용할 수 있습니다.
세계의 mRNA 암백신 시장에 대해 조사했으며, 시장의 개요와 약제 동향, 임상시험 동향, 지역별 동향 및 시장에 참여하는 기업의 경쟁 구도 등을 정리하여 전해드립니다.
Global mRNA Cancer Vaccines Clinical Trials & Market Future Outlook 2024 Report Highlights:
From that time impetuous when mRNA vaccines were utilized for the management of coronavirus, in 2019, clinical researchers are working insistently with the intention of using mRNA vaccines for the treatment of cancer ailments. Building on the triumph of mRNA vaccine to cure coronavirus, copious researchers believed that cutting edge mRNA vaccines can be used to treat cancer patients owing to its exclusive mode of action. For that reason, it can be forecast that the market for mRNA cancer vaccine is expected to advance further in the imminent years. Currently, the market for this segment exists in the US coupled with China in terms of research and development; however, other regions, like European countries, are also an emerging area as evident from preclinical and clinical studies.
Until now, no mRNA cancer vaccines have entered into the commercial global market, with 2 mRNA vaccines contenders, CMB-305 in conjugation with mRNA 4157, being in the late phase of development (phase III), it can be prophesied that first breakthrough mRNA cancer vaccine will enter into the global market in upcoming 5-7 years and we contemplates that the casement of first mRNA cancer vaccine will result in an overall revenue of US$ 100 Million after its approval within 12-18 months. According to KuicK Research recent study on global mRNA clinical landscape, 3 to 4 mRNA cancer vaccines are likely to commercially enter the market in following decennium. As well as, with cumulative sales clenches plausibility of more than US$ 5 Billion in years to come.
For that reason, several mRNA cancer vaccines preclinical and clinical trials are ongoing in the domain. For instance, The V Foundation for Cancer Research in collaboration with University of Florida are planning to initiate a phase I/II clinical trial in order to examine the safety as well as immunologic activity of RNA lipid Particle (RNA-LP) Vaccines in patients with recurrent pulmonary osteosarcoma. It is an interventional study, which has an estimated study start date in August 2024 and is projected to be complete by October 2026.
Above this, the domain of mRNA cancer vaccine is experiencing trailblazing growth due to increasing research collaboration, and investments. For instance, in June 2024, Moderna has joined hands with Merck by announcing 3 year data for mRNA-4157 (V940) in combination with Keytruda (pembrolizumab) which established sustained improvement in patients suffering from high-risk stage III/IV melanoma following complete resection. Moreover, the University of Texas MD Anderson Cancer Center in addition to CureVac N.V. proclaimed a co-development along with licensing agreement in order develops novel mRNA-based cancer vaccines in April 2024.
Coupled with collaborations, advancement in technological and drug delivery is also another aspect which is influencing global mRNA cancer vaccine growth. For instance, in August 2023, healthcare professionals from Johns Hopkins Medicine have developed a nanoparticle based design which clenches plausibility to enhance mRNA cancer vaccine delivery.
Hitherto, the global sector of mRNA cancer vaccine has acknowledged an avant-garde growth, fueled by the noteworthy progression in research and development, in addition to the transformative potential of this innovative treatment modality. Accumulating studies have revealed that mRNA cancer vaccines clenches potential of treating cancer and exemplifies safer as well as well tolerated profile, thereby, offering novel avenue. Albeit, mRNA cancer vaccines are predominately used to treat solid tumors; nonetheless, treatment of hematological cancer malignancies by mRNA vaccines are likewise to be utilized in imminent years.
There is a favorable prospect in addition to development mRNA cancer vaccine in the global market but with a number of hardships and Achilles heels, like long term effectiveness and competition from other therapies. In the meantime, there exists a robust and cumbersome pipeline of clinical trials; hence, it is expected that the realm of mRNA cancer vaccine clenches enthusiastic forthcoming; representing an opportunity for pharma companies to advance the realm of mRNA cancer vaccine.
Therapeutic